


In the Claims:


1-53. Cancelled.

54. Cancelled


55. (Previously presented) The compound according to claim 88 wherein B is




56. (Previously presented) The compound according to claim 55 wherein R<sup>3</sup> is



57. (Previously presented) The compound according to claim 56 wherein R is F, Cl, Br, I,




58. (Previously presented) The compound according to claim 56 wherein R is CH<sub>3</sub>, R<sup>3</sup> is



59. (Previously presented) The compound according to claim 58 wherein R<sup>3a</sup> and R<sup>3b</sup> are both H.

60. (Previously presented) The compound according to claim 58 wherein R<sup>2</sup> is H.


61. (Previously presented) The compound according to claim 88 which is




62. (Previously presented) The compound according to claim 61 wherein  $R^2$  is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

63. (Previously presented) The compound according to claim 61 wherein  $R^2$  is H.


64. (Previously presented) The compound according to claim 88 wherein B is



65. (Currently amended) The compound according to claim 64 wherein  $R^3$  is



66. (Previously presented) The compound according to claim 65 wherein R is H, F, Cl,



X is H, C<sub>1</sub>-C<sub>4</sub> alkyl, F, Cl, Br or I.


67. (Previously presented) The compound according to claim 64 wherein R is CH<sub>3</sub>, R<sup>3</sup> is -(CH<sub>2</sub>)<sub>n</sub>-C≡C-R<sub>a</sub>, n is 0 and R<sub>a</sub> is H.

68. (Previously presented) The compound according to claim 67 wherein R<sup>3a</sup> and R<sup>3b</sup> are both H.


69. (Previously presented) The compound according to claim 68 wherein R<sup>2</sup> is H.

70. Cancelled.


71. (Previously presented) The composition according to claim 89 wherein B is



72. (Previously presented) The composition according to claim 71 wherein R<sup>3</sup> is



73. (Previously presented) The composition according to claim 72 wherein R is F, Cl, Br,



I, C<sub>1</sub>-C<sub>3</sub> alkyl, -C≡C-R<sub>a</sub>,


X is H, C<sub>1</sub>-C<sub>4</sub> alkyl, F, Cl, Br or I.

74. (Previously presented) The composition according to claim 71 wherein R is CH<sub>3</sub>, R<sup>3</sup> is -(CH<sub>2</sub>)<sub>n</sub>-C≡C-R<sub>a</sub>, n is 0 and R<sub>a</sub> is H.

75. (Previously presented) The composition according to claim 74 wherein R<sup>3a</sup> and R<sup>3b</sup> are both H.

76. (Previously presented) The composition according to claim 75 wherein R<sup>2</sup> is H.


77. (Previously presented) The composition according to claim 89 wherein said compound is




78. (Previously presented) The composition according to claim 77 wherein R<sup>2</sup> is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

79. (Previously presented) The composition according to claim 77 wherein R<sup>2</sup> is H.


80. (Previously presented) The composition according to claim 89 wherein B is



81. (Currently amended) The composition according to claim 80 wherein R<sup>3</sup> is



82. (Previously presented) The composition according to claim 81 wherein R is H, F, Cl,




83. (Previously presented) The composition according to claim 80 wherein R is CH<sub>3</sub>, R<sup>3</sup> is  $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$ , n is 0 and R<sub>a</sub> is H.

84. (Previously presented) The composition according to claim 83 wherein R<sup>3a</sup> and R<sup>3b</sup> are both H.

85. (Previously presented) The composition according to claim 84 wherein R<sup>2</sup> is H.

86. (Previously presented) The composition according to claim 89 wherein said compound is






Where R<sup>1</sup> is H or an acyl group; and

$R^2$  is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

87. (Previously presented) The composition according to claim 86 wherein  $R^1$  is H and  $R^2$  is H.

88. (Currently amended) A compound according to the formula:




Wherein B is

or

;


R is H, F, Cl, Br, I,  $C_1$ - $C_4$  alkyl,  $-C\equiv N$ ,  $-C\equiv C-R_a$ ,



X is H,  $C_1$ - $C_4$  alkyl, F, Cl, Br or I;

$R^1$  is H, an acyl group, a  $C_1$ - $C_{20}$  alkyl or an ether group;


$R^2$  is H, an acyl group, a  $C_1$ - $C_{20}$  alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a




Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R<sup>8</sup> is H or a C<sub>1</sub>-C<sub>20</sub> alkyl or ether group;

R<sup>3</sup> is a C<sub>3</sub> or C<sub>4</sub> alkyl group,  $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$ ,  $\begin{array}{c} \text{H} \\ \diagup \\ \text{---}(\text{CH}_2)_n \end{array} \text{C}=\text{C} \begin{array}{c} \text{Y} \\ \diagdown \\ \text{H} \end{array}$  or  $\begin{array}{c} \text{H} \\ \diagup \\ \text{---}(\text{CH}_2)_n \end{array} \text{C}=\text{C} \begin{array}{c} \text{H} \\ \diagdown \\ \text{Y} \end{array}$



when B is \_\_\_\_\_, and R<sup>3</sup> is a C<sub>3</sub> or C<sub>4</sub> alkyl group or a  $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$



group when B is \_\_\_\_\_;

R<sup>3a</sup> and R<sup>3b</sup> are each independently H, F, Cl, Br and I;

R<sub>a</sub> is H, F, Cl, Br, I, or -C<sub>1</sub>-C<sub>4</sub> alkyl;



Y is H, F, Cl, Br, I or -C<sub>1</sub>-C<sub>4</sub> alkyl;

k is 0, 1 or 2; and

n is 0, 1, 2, 3, 4 or 5;


or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof.

89. A pharmaceutical composition comprising an effective amount of a compound for use in the treatment of a viral disease state, disorder or a condition associated with a viral disease state according to the formula:




Wherein B is

or



;

R is H, F, Cl, Br, I, C<sub>1</sub>-C<sub>4</sub> alkyl, -C≡N, -C≡C-R<sub>a</sub>,




X is H, C<sub>1</sub>-C<sub>4</sub> alkyl, F, Cl, Br or I;

R<sup>1</sup> is H, an acyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl or an ether group;



R<sup>2</sup> is H, an acyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a






Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R<sup>8</sup> is H or a C<sub>1</sub>-C<sub>20</sub> alkyl or ether group;



when B is \_\_\_\_\_, and R<sup>3</sup> is a C<sub>3</sub> or C<sub>4</sub> alkyl group or a  $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$



group when B is \_\_\_\_\_;

R<sup>3a</sup> and R<sup>3b</sup> are each independently H, F, Cl, Br and I;

R<sub>a</sub> is H, F, Cl, Br, I, or -C<sub>1</sub>-C<sub>4</sub> alkyl;

Y is H, F, Cl, Br, I or -C<sub>1</sub>-C<sub>4</sub> alkyl;



k is 0, 1 or 2; and

n is 0, 1, 2, 3, 4 or 5;



or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof in combination with a pharmaceutically acceptable carrier, additive or excipient.

Claims 90-91 are new:

90. (New) A compound according to the formula:




Wherein B is

R is H, F, Cl, Br, I, C<sub>1</sub>-C<sub>4</sub> alkyl, -C≡N, -C≡C-R<sub>a</sub>,  or  ;

X is H, C<sub>1</sub>-C<sub>4</sub> alkyl, F, Cl, Br or I;


R<sup>1</sup> is H, an acyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl or an ether group;

R<sup>2</sup> is H, an acyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a



Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R<sup>8</sup> is H or a C<sub>1</sub>-C<sub>20</sub> alkyl or ether group;



R<sup>3a</sup> and R<sup>3b</sup> are each independently H, F, Cl, Br and I;

R<sub>a</sub> is H, F, Cl, Br, I, or -C<sub>1</sub>-C<sub>4</sub> alkyl;


Y is H, F, Cl, Br, I or -C<sub>1</sub>-C<sub>4</sub> alkyl;


k is 0, 1 or 2; and

n is 3, 4 or 5;



or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof.

91. A pharmaceutical composition comprising an effective amount of a compound for use in the treatment of a viral disease state, disorder or a condition associated with a viral disease state according to the formula:






Wherein B is

R is H, F, Cl, Br, I, C<sub>1</sub>-C<sub>4</sub> alkyl, -C≡N, -C≡C-R<sub>a</sub>,  or  ;

X is H, C<sub>1</sub>-C<sub>4</sub> alkyl, F, Cl, Br or I;



R<sup>1</sup> is H, an acyl group, a C<sub>1</sub>—C<sub>20</sub> alkyl or an ether group;

R<sup>2</sup> is H, an acyl group, a C<sub>1</sub>—C<sub>20</sub> alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a



Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R<sup>8</sup> is H or a C<sub>1</sub>-C<sub>20</sub> alkyl or ether group;

R<sup>3</sup> is  or  ;

R<sup>3a</sup> and R<sup>3b</sup> are each independently H, F, Cl, Br and I;

R<sub>a</sub> is H, F, Cl, Br, I, or -C<sub>1</sub>-C<sub>4</sub> alkyl;

Y is H, F, Cl, Br, I or -C<sub>1</sub>-C<sub>4</sub> alkyl;

k is 0, 1 or 2; and

n is 0, 1, 2,3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof in combination with a pharmaceutically acceptable carrier, additive or excipient.